Blastic plasmacytoid dendritic cell neoplasm
Revision as of 01:10, 10 May 2019 by Warner-admin (talk | contribs) (Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 50%"|Study !style="width: 50%"|Evidence" to "{| class="wikitable" style="width: 50%; text-align:center;" !style="width: 25%"|Study !style="width: 25%"|Evidence")
| Section editor | |
|---|---|
 |
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO  mwschoen
|
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tagraxofusp monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Frankel et al. 2014 | Phase I/II, <20 pts |
Chemotherapy
- Tagraxofusp (Elzonris) 12 mcg/kg IV over 15 minutes once per day on days 1 to 5
21-day cycles
References
- Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article PubMed